Abstract

RECENT ADVANCES IN NASAL FORMULATIONS AND DEVICES USED IN PULMONARY DRUG DELIVERY

T. Praveen Kumar*¹, M. Indira Vani¹, D. Yamini¹, P. Narayana Raju¹,G. Nagarjuna Reddy¹

Department of Pharmaceutics, K. L. R Pharmacy College,Paloncha, Khammam, Andhra Pradesh, India.

ABSTRACT

Pulmonary drug delivery has gained tremendous scientific interest in recent years and has progressed within the context of treatment for lung diseases. Lung is an attractive environment for bio molecules, which are highly susceptible to enzymatic degradation in the gastrointestinal tract as well as hepatic degradation. Pulmonary route is a non-invasive administration for systemic delivery of therapeutic agents (mainly peptides and proteins). Lungs provide a large absorptive surface area but extremely thin (0.1 μm – 0.2 μm) absorptive mucosal membrane and good blood supply. Intra tracheal administration is a first approach in lung drug delivery in vivo. In inhalation therapy most common devices used were nebulizer, Metered dose inhaler (MDI), and Dry powder inhaler (DPI). Pulmonary drug delivery is used for management of COPD and Asthma. Last few years techniques and new drug delivery devices intended to deliver drugs into the lungs have been widely developed. Pulmonary drug delivery can also be used to treat Diabetes, angina pectoris, cancer, bone disorders, tuberculosis, migraine acute lung injury and others. Liposomes, nano and micro particles, cyclodextrins, micro emulsions, micelles, suspensions, or solutions are all examples of the pharmaceutical drug carriers that have been successfully used to target drugs into lungs. This review discusses the approaches and devices required to be administer drug into the lungs.

Keywords: Asthma, Lungs, Nanoparticles, Nebulizer, Non-invasive, Pulmonary drug